4-(4-氯苯基)-4-哌啶羧酸 | 760943-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-氯苯基)-4-哌啶羧酸
• 英文名称: 4-(4-Chlorophenyl)piperidine-4-carboxylic acid
• CAS: 760943-97-3
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.7
• InChiKey: HVOKAUOIVHUVCF-UHFFFAOYSA-N

物化性质

• 沸点：
  399.3±42.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Piperidine derivatives and methods of use
  申请人：Zhang Penglie

  公开号：US20070088036A1

  公开（公告）日：2007-04-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并具有体内抗炎活性。这些化合物通常是单环和双环化合物，可用于制药组合物、治疗CCR1介导疾病的方法，以及作为竞争性CCR1拮抗剂鉴定的控制物。
• RHO KINASE INHIBITORS
  申请人：Bosanac Todd

  公开号：US20080161297A1

  公开（公告）日：2008-07-03

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  揭示了一种新颖的取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物，可用作Rho激酶的抑制剂，用于治疗通过Rho激酶活性介导或维持的各种疾病和疾病，包括心血管疾病，包含这些化合物的药物组合物，使用这些化合物的方法以及制备这些化合物的方法。
• Chemical compounds
  申请人：Alvaro Giuseppe

  公开号：US20060128752A1

  公开（公告）日：2006-06-15

  The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  本发明涉及式（I）的环状胺衍生物，其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基；R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基，可选地被卤素、氰基或C1-4烷氧基取代；R2代表氢或C1-4烷基；R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基；R5代表三氟甲基、S（O）tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基；R6代表氢或（CH2）rR7；R7代表氢、C37环烷基、NH（C1-4烷基OC1-4烷氧基）、NH（C1-4烷基）、N（C1-4烷基）2、OC（O）NR9R8、NR8C（O）R9或C（O）NR9R8；R9和R8独立地代表氢、C1-4烷基或C3-7环烷基；m代表零或1至4的整数；n代表1或2；p为零或1至3的整数；q为1至3的整数；r为1至4的整数；t为0、1或2；但当m为0，p为2，q、r和n均为1，R1、R2、R3、R4、R5和R7均为氢，R为氯时，R5不为碘；以及其药学上可接受的盐和溶剂化合物；其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
• Compounds for Treating Protein-Kinase Mediated Disorders
  申请人：Berdini Valerio

  公开号：US20080275029A1

  公开（公告）日：2008-11-06

  The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B; wherein the ring Q is a benzene ring; J 2 -J 1 is N═CR 7 or R 1a N—CO; G is OH or NR 5 R 6 ; E is CONR 7 , NR 7 CO, C(R 8 )═C(R 8 ) or (X) m (CR 8 R 8a ) n where X is O, S or NR 7 ; provided that when J 2 -J 1 is R 1a N—CO, E is other than NR 7 CO; m and n are each 0 or 1, where m+n=1 or 2; A is a bond and R 4 and R 4a are absent or A is a saturated optionally substituted C 1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R 1 , R 1a , R 2 , and R 3 are each H; halogen; C 1-6 hydrocarbyl optionally substituted by halogen, OH or C 1-2 alkoxy; CN; CONHR 8 ; NH 2 ; NHCOR 10 or NHCONHR 10 ; R 4 is H or C 1-4 alkyl; R 4a is H, C 1-4 alkyl or a group R 9 ; R 5 and R 6 are each selected from H, R 9 and C 1-4 hydrocarbyl optionally substituted by halogen, C 1-2 alkoxy or R 9 ; or NR 5 R 6 forms a saturated 4-7 membered monocyclic heterocyclic group; R 7 is H or C 1-4 alkyl; R 8 and R 8a each H or saturated C 1-4 hydrocarbyl optionally substituted by fluorine; R 9 is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R 4 , R 4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR 5 R 6 , R 4 and A form a saturated 4-7 membered monocyclic heterocycle; or R 4 , together with R 7 or R 8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR 5 R 6 and R 7 or R 8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R 10 is optionally substituted phenyl or benzyl.

  该发明提供了一种式(I)的化合物或其盐、溶剂化物、互变异构体或N-氧化物，用于治疗或预防由蛋白激酶A和/或蛋白激酶B介导的疾病状态或病情；其中，环Q是苯环；J2-J1是N═CR7或R1aN—CO；G是OH或NR5R6；E是CONR7、NR7CO、C(R8)═C(R8)或(X)m(CR8R8a)n，其中X为O、S或NR7；但当J2-J1是R1aN—CO时，E为除NR7CO之外的其他化合物；m和n各为0或1，其中m+n=1或2；A是键，R4和R4a不存在或A是饱和的可选取代的C1-7烃链连接基，在E和G之间具有最大链长为5个原子，链连接基中的一个碳原子可被O或N取代；R1、R1a、R2和R3各为H、卤素、C1-6烃基，可选取代卤素、OH或C1-2烷氧基、CN、CONHR8、NH2、NHCOR10或NHCONHR10；R4为H或C1-4烷基；R4a为H、C1-4烷基或基团R9；R5和R6各为H、R9和C1-4烃基，可选取代卤素、C1-2烷氧基或R9；或NR5R6形成饱和的4-7成员的单环杂环基；R7为H或C1-4烷基；R8和R8a各为H或饱和的C1-4烃基，可选取代氟；R9为含有最多3个环杂原子（选自N、O和S）的单环或双环碳环或杂环基；或R4、R4a和A一起形成饱和的单环4-7成员杂环；或NR5R6、R4和A形成饱和的4-7成员单环杂环；或R4与R7或R8和A、E一起形成4-7成员饱和的单环杂环；或NR5R6与R7或R8一起与A和E形成4-7成员饱和的单环杂环；R10为可选取代苯基或苄基。
• Rho kinase inhibitors
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US10624882B2

  公开（公告）日：2020-04-21

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  所公开的是新型取代的 2H-isoquinolin-1-one 和 3H-quinazolin-4-one 衍生物，可作为 Rho 激酶的抑制剂，用于治疗通过 Rho 激酶的活性介导或维持的各种疾病和失调，包括心血管疾病；还公开了包含此类化合物的药物组合物、使用此类化合物的方法和制造此类化合物的工艺。